Sabby Management’s MAIA Biotechnology MAIA Stock Holding History

Sabby Management’s Portfolio MAIA Stock Details MAIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-130,510	Closed	-$153K	–	65
2023 Q4	$153K	Buy	+130,510	New	+$211K	0.15%	30

Other funds holding MAIA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWM

Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management's MAIA Position: Q1 2024 in Review

Sabby Management sold out of MAIA Biotechnology (MAIA) in Q1 2024, closing a stake of 130,510 shares — an estimated $153K sold.

Sabby Management first reported a position in MAIA in Q4 2023 and held it in 1 quarter. The position peaked at $153K in Q4 2023. 20 funds tracked by Wall St. Rank hold MAIA as of Q1 2024.

Sabby Management reported no remaining MAIA Biotechnology position as of Q1 2024 after selling out during the quarter.
Sabby Management sold 130,510 MAIA Biotechnology shares in Q1 2024, an estimated $153K.
Sabby Management first reported a position in MAIA Biotechnology in Q4 2023 and held it in 1 quarter.
Sabby Management's MAIA Biotechnology position peaked at $153K in Q4 2023.
20 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q1 2024.

Based on Sabby Management's 13F filing for Q1 2024, filed 15 May 2024.